Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative
|
By LabMedica International staff writers Posted on 09 Oct 2024 |

Seegene (Seoul, South Korea), a leading PCR molecular diagnostics company, and Werfen (Barcelona, Spain), a global diagnostics specialist, have finalized a partnership agreement as part of a technology-sharing initiative. The agreement outlines plans for the two companies to establish a NewCo in Spain, named Werfen-Seegene, following required government approvals, expected by the first half of 2025. This partnership expands on the technology-sharing initiative's momentum, which began with the first NewCo partnership in March 2023, alongside Hylabs (Rehovot, Israel), another leading diagnostic company.
The technology-sharing initiative aims to globally share Seegene’s cutting-edge diagnostic and data analysis technologies, such as syndromic real-time PCR and an automated product development system (SGDDS). Seegene’s syndromic real-time PCR technology is a significant innovation, enabling the simultaneous detection of up to 14 pathogens in a single reaction tube, providing quantitative data for each target. Partnering companies will work with local scientists and specialists to develop diagnostic tests tailored to their regional needs across various human, animal, and plant diseases. With climate change and rising outbreaks as pressing concerns, the broader vision of the initiative is to build "a world free from diseases"—a future where infectious diseases, cancer, and other health challenges are minimized for both humans and animals.
Seegene has also formed strategic alliances with Microsoft (Redmond, WA, USA) and Springer Nature (Berlin, Germany) to support the technology-sharing initiative. The collaboration with Microsoft aims to streamline product development by integrating advanced IT systems and AI-powered data analysis, benefiting companies worldwide. Springer Nature, through its Open Innovation Program (OIP) and the ‘Nature Awards MDx Impact Grants’ launched in 2024, is fostering innovation in PCR diagnostic technologies. The initiative aims to further expand these programs to support NewCos in collaborating with local researchers and experts for product development across various fields.
Werfen-Seegene will prioritize developing diagnostics for infectious diseases, including antimicrobial and drug resistance testing, viral load testing, monitoring organ transplant patients, sexually transmitted infections (STIs), and emerging regional diseases. Leveraging Werfen’s strong local infrastructure and network, the NewCo will create products tailored to Spain’s healthcare needs. Spain, the fourth-largest in vitro diagnostics (IVD) market in Europe, will serve as a strategic hub for expanding the initiative across Europe and globally. Additionally, Werfen-Seegene will lead efforts to secure CE-IVDR approval for in vitro diagnostic medical devices, further driving the expansion of these innovations.
"Over the past decade, our collaboration with Seegene has showcased the significant impact of their syndromic PCR diagnostic tests on healthcare," said Carlos Pascual, CEO of Werfen. “We are excited to leverage Seegene's unparalleled technology and manufacturing expertise to develop products tailored for the Spanish and Portuguese market, where there is a high demand for rapid product development due to the frequent emergence of new infectious diseases and viral mutations. This partnership with Seegene will enable us to expand our footprint and respond swiftly to any outbreaks.”
"We have high expectations for this NewCo, which will combine Werfen's extensive business experience with Seegene's leading syndromic product development and production capabilities," added Dr. Jong-Yoon Chun, CEO and founder of Seegene. “We will continue to share our technology with leading global companies and countries that are interested in our technology-sharing initiative. Werfen-Seegene will play a pivotal role in accelerating global expansion of our initiative.”
Related Links:
Seegene
Werfen
Hylabs
Springer Nature
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more







